REGN Regeneron Pharmaceuticals Inc

Price (delayed)

$1,064.41

Market cap

$117.28B

P/E Ratio

29.47

Dividend/share

N/A

EPS

$36.12

Enterprise value

$117.38B

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities , it ...

Highlights
The equity has grown by 15% year-on-year and by 3.9% since the previous quarter
The revenue has increased by 6% YoY
REGN's price to earnings (P/E) is 77% higher than its 5-year quarterly average of 16.7 and 31% higher than its last 4 quarters average of 22.6
The quick ratio has contracted by 9% from the previous quarter and by 3.1% YoY

Key stats

What are the main financial stats of REGN
Market
Shares outstanding
110.19M
Market cap
$117.28B
Enterprise value
$117.38B
Valuations
Price to book (P/B)
4.33
Price to sales (P/S)
8.76
EV/EBIT
28.54
EV/EBITDA
25.81
EV/Sales
8.96
Earnings
Revenue
$13.1B
EBIT
$4.11B
EBITDA
$4.55B
Free cash flow
$4.06B
Per share
EPS
$36.12
Free cash flow per share
$37.71
Book value per share
$245.91
Revenue per share
$121.52
TBVPS
$309.01
Balance sheet
Total assets
$34.37B
Total liabilities
$7.38B
Debt
$2.7B
Equity
$26.99B
Working capital
$15.29B
Liquidity
Debt to equity
0.1
Current ratio
5.27
Quick ratio
4.4
Net debt/EBITDA
0.02
Margins
EBITDA margin
34.7%
Gross margin
86.3%
Net margin
29.4%
Operating margin
29.4%
Efficiency
Return on assets
11.8%
Return on equity
15.1%
Return on invested capital
14.4%
Return on capital employed
13.4%
Return on sales
31.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

REGN stock price

How has the Regeneron Pharmaceuticals stock price performed over time
Intraday
-0.5%
1 week
-2.79%
1 month
1.07%
1 year
44.89%
YTD
21.19%
QTD
1.27%

Financial performance

How have Regeneron Pharmaceuticals's revenue and profit performed over time
Revenue
$13.1B
Gross profit
$11.31B
Operating income
$3.85B
Net income
$3.86B
Gross margin
86.3%
Net margin
29.4%
Regeneron Pharmaceuticals's operating margin has decreased by 18% YoY and by 4.9% QoQ
The net margin has decreased by 13% YoY and by 2.3% from the previous quarter
The operating income fell by 13% YoY and by 4.8% QoQ
Regeneron Pharmaceuticals's net income has decreased by 8% YoY and by 2.4% QoQ

Growth

What is Regeneron Pharmaceuticals's growth rate over time

Valuation

What is Regeneron Pharmaceuticals stock price valuation
P/E
29.47
P/B
4.33
P/S
8.76
EV/EBIT
28.54
EV/EBITDA
25.81
EV/Sales
8.96
REGN's price to earnings (P/E) is 77% higher than its 5-year quarterly average of 16.7 and 31% higher than its last 4 quarters average of 22.6
The company's EPS fell by 8% YoY and by 2.5% QoQ
REGN's price to book (P/B) is 21% more than its last 4 quarters average of 3.6 and 6% more than its 5-year quarterly average of 4.1
The equity has grown by 15% year-on-year and by 3.9% since the previous quarter
The P/S is 42% higher than the 5-year quarterly average of 6.2 and 26% higher than the last 4 quarters average of 7.0
The revenue has increased by 6% YoY

Efficiency

How efficient is Regeneron Pharmaceuticals business performance
Regeneron Pharmaceuticals's return on invested capital has decreased by 27% YoY and by 8% QoQ
Regeneron Pharmaceuticals's return on equity has decreased by 21% YoY and by 6% QoQ
The return on assets has declined by 20% year-on-year and by 6% since the previous quarter
The company's return on sales fell by 18% YoY and by 3.7% QoQ

Dividends

What is REGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for REGN.

Financial health

How did Regeneron Pharmaceuticals financials performed over time
REGN's total assets is up by 14% year-on-year and by 3.9% since the previous quarter
Regeneron Pharmaceuticals's total liabilities has increased by 12% YoY and by 3.8% QoQ
The debt is 90% less than the equity
The equity has grown by 15% year-on-year and by 3.9% since the previous quarter
REGN's debt to equity is down by 9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.